Marrow stromal stem cells, first identified in 1968 by Friedenstein and colleagues, are multipotent cells that can differentiate into various connective tissues, including bone, cartilage, and adipose tissue. These cells, known as colony-forming units-fibroblastic (CFU-Fs), are found in the bone marrow stroma and can be transplanted to generate structures like ossicles, which mimic the histology and architecture of bone. Transplantation studies have shown that donor-derived cells can form bone, cartilage, and adipose tissue, while host-derived cells can differentiate into hematopoietic cells. These findings highlight the physiological relevance of stromal cells and their role in tissue regeneration. Marrow stromal cells are established in the developing marrow cavity after a bony collar forms, and they play a crucial role in hematopoiesis by providing a supportive microenvironment. The transcription factor cbfa1 is essential for osteogenic differentiation and bone formation, and its expression is upstream of stromal cell ontogeny. Stromal cells can differentiate into multiple lineages, including osteoblasts, adipocytes, and chondrocytes, and their plasticity allows them to shift between these phenotypes based on metabolic needs. The plasticity of marrow stromal cells extends to their functions in development and postnatal growth, as they can adapt to changing environmental cues and remodel the extracellular matrix. This plasticity is distinct from the hematopoietic system, where differentiation is generally irreversible. Stromal cells can also give rise to different tissues, including bone, cartilage, and adipose tissue, and their ability to do so has led to interest in their potential for therapeutic applications. Marrow stromal cells have been used to model skeletal diseases, such as fibrous dysplasia, by transplanting mutated stromal cells and observing the resulting phenotypic abnormalities. These cells have potential clinical applications, including the repair of skeletal defects, gene therapy, and the treatment of systemic bone diseases. However, systemic transplantation of stromal cells remains challenging due to their differences from hematopoietic stem cells and the difficulty in tracking their engraftment and function in vivo. Despite their potential, the clinical application of marrow stromal cells requires further research to understand their behavior in vivo and to develop effective methods for their use in therapy. The study of marrow stromal cells continues to provide insights into stem cell biology, tissue regeneration, and the plasticity of somatic cells.Marrow stromal stem cells, first identified in 1968 by Friedenstein and colleagues, are multipotent cells that can differentiate into various connective tissues, including bone, cartilage, and adipose tissue. These cells, known as colony-forming units-fibroblastic (CFU-Fs), are found in the bone marrow stroma and can be transplanted to generate structures like ossicles, which mimic the histology and architecture of bone. Transplantation studies have shown that donor-derived cells can form bone, cartilage, and adipose tissue, while host-derived cells can differentiate into hematopoietic cells. These findings highlight the physiological relevance of stromal cells and their role in tissue regeneration. Marrow stromal cells are established in the developing marrow cavity after a bony collar forms, and they play a crucial role in hematopoiesis by providing a supportive microenvironment. The transcription factor cbfa1 is essential for osteogenic differentiation and bone formation, and its expression is upstream of stromal cell ontogeny. Stromal cells can differentiate into multiple lineages, including osteoblasts, adipocytes, and chondrocytes, and their plasticity allows them to shift between these phenotypes based on metabolic needs. The plasticity of marrow stromal cells extends to their functions in development and postnatal growth, as they can adapt to changing environmental cues and remodel the extracellular matrix. This plasticity is distinct from the hematopoietic system, where differentiation is generally irreversible. Stromal cells can also give rise to different tissues, including bone, cartilage, and adipose tissue, and their ability to do so has led to interest in their potential for therapeutic applications. Marrow stromal cells have been used to model skeletal diseases, such as fibrous dysplasia, by transplanting mutated stromal cells and observing the resulting phenotypic abnormalities. These cells have potential clinical applications, including the repair of skeletal defects, gene therapy, and the treatment of systemic bone diseases. However, systemic transplantation of stromal cells remains challenging due to their differences from hematopoietic stem cells and the difficulty in tracking their engraftment and function in vivo. Despite their potential, the clinical application of marrow stromal cells requires further research to understand their behavior in vivo and to develop effective methods for their use in therapy. The study of marrow stromal cells continues to provide insights into stem cell biology, tissue regeneration, and the plasticity of somatic cells.